Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270760 | 0.93 | KCNH2 (0.52) | CCR5KCNH2ALDH1A1 | |
| SCHEMBL3278114 | 0.92 | CCR5 (0.51) | CCR5KCNH2 | |
| SCHEMBL3271481 | 0.92 | CCR5 (0.55) | CCR5KCNH2 | |
| SCHEMBL3270053 | 0.91 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL3270910 | 0.88 | CCR5 (0.48) | CCR5KCNH2 | |
| SCHEMBL3275943 | 0.87 | CCR5 (0.65) | CCR5 | |
| SCHEMBL3271615 | 0.87 | CCR5 (0.54) | CCR5KCNH2ALDH1A1 | |
| SCHEMBL3273291 | 0.86 | CCR5 (0.55) | CCR5 | |
| SCHEMBL3271849 | 0.86 | KCNH2 (0.51) | CCR5KCNH2 | |
| SCHEMBL3269817 | 0.86 | CCR5 (0.54) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066674-B1 | OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | claimed |
| US-20080103125-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103125-A1 | Heterocylic antiviral compounds | CCR5, ACKR3, CXCR3 | CCR5 1/4885KCNH2 3419/4885ALDH1A1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.